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Little controversies remain that the initiation of insulin is an 
effective therapy to achieve glycemic control when escalating 
doses of oral hypoglycemic agents (OHAs) are no longer effec-
tive in achieving and maintaining a patient’s target HbA1c lev-
els. However, there are some dissent within clinicians on the 
optimal approach for initiating insulin analogue therapy, in-
cluding when to start insulin, types of insulin preparations 
(postprandial, basal, basal and bolus, and premixed insulins) 
and how to implement insulin regimen (calculating starting 
insulin doses, numbers of injections and morning to evening 
ratio in total dose of twice daily premixed insulin regimen etc.). 
Despite the lack of established guidelines clearly providing an-
swers for the above questions, some consensus have been made 
and recommended on these issues [1-3].
 In the current study by Song et al. [4], they clearly demon-
strated the efficacy and safety of biphasic insulin aspart 30/70 
(henceforth biphasic insulin analogue [BIA]) with improving 
A1c from 9.2% to 8.2%. In the recent results of A1chieve study 
conducted in Korea (henceforth Kor-A1chieve) [5], it showed 
a definite 24-week reductions in HbA1c from 10.0% to 8.3% 
in subjects treated with BIA +/- OHAs. Based on the consen-
sus on how to use insulin analogues [1-3], we raise the queries 
on their study design and its relevance A1c reduction.
 First, Song et al. [4] adopted the initial daily dose of 0.3 U/
kg body weight with single injection (≤30 units) at breakfast 
or twice daily (>30 units) at morning and evening with 2:1 ra-
tio. In current consensus [2,3] and Sapporo 1-2-3 study [6] 
conducted in Japan, they recommended and adopted 1:1 ratio 
in total dose of twice daily BIA. Furthermore, Sapporo 1-2-3 
study adopted an evening single injection. However, no ratio-
nal explanations on time of insulin injection and split dose of 
BIA were given by investigators.
 Second, Song et al. [4] also adopted the protocol of stopping 
all previous OHAs during the transition to BIA. The consensus 
statement on BIA [3] recommended the discontinuation of 
sulfonylurea and continuation of metformin when switching 
to BIA. Although the authors commented on the need for OHAs 
combination in the use of BIA, they did not suggest on how to 
use OHAs in the initiation of BIA.
 Third, Song et al. [4] showed a 2.7 kg weight gain at 16-week 
study endpoint. In contrary to previous reports on BIA studies 
conducted in Korea (Kor-A1chieve reference, [5,7]), weight 
gains by the initiation of insulin were significant in this study.
 Finally, it could be of interest that might tell us whom to and 
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how to initiate the BIA in Korean subjects.
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